{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T03:36:31Z","timestamp":1777088191717,"version":"3.51.4"},"reference-count":59,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.mayocp.2013.11.009","type":"journal-article","created":{"date-parts":[[2014,1,8]],"date-time":"2014-01-08T07:15:31Z","timestamp":1389165331000},"page":"241-253","source":"Crossref","is-referenced-by-count":83,"title":["Management of Hepatic Encephalopathy in the Hospital"],"prefix":"10.1016","volume":"89","author":[{"given":"Michael D.","family":"Leise","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John J.","family":"Poterucha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick S.","family":"Kamath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. Ray","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.mayocp.2013.11.009_bib1","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/j.1365-2036.2011.04590.x","article-title":"Review article: the design of clinical trials in hepatic encephalopathy: an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement","volume":"33","author":"Bajaj","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.mayocp.2013.11.009_bib2","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1053\/jhep.2002.31250","article-title":"Hepatic encephalopathy: definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998","volume":"35","author":"Ferenci","year":"2002","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.mayocp.2013.11.009_bib3","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0168-8278(99)80144-5","article-title":"Prognostic significance of hepatic encephalopathy in patients with cirrhosis","volume":"30","author":"Bustamante","year":"1999","journal-title":"J\u00a0Hepatol"},{"issue":"8","key":"10.1016\/j.mayocp.2013.11.009_bib4","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1111\/j.1365-2036.2007.03464.x","article-title":"The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy: a decision analysis","volume":"26","author":"Huang","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.mayocp.2013.11.009_bib5","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/lt.21129","article-title":"Hepatic encephalopathy as a predictor of survival in patients with end-stage liver disease","volume":"13","author":"Stewart","year":"2007","journal-title":"Liver Transpl"},{"issue":"9","key":"10.1016\/j.mayocp.2013.11.009_bib6","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.cgh.2012.05.016","article-title":"In-hospital mortality and economic burden associated with hepatic encephalopathy in the United States from 2005 to 2009","volume":"10","author":"Stepanova","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.mayocp.2013.11.009_bib7","first-page":"945A","article-title":"Assessing treatment patterns in patients with overt hepatic encephalopathy","volume":"56","author":"Neff","year":"2012","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.mayocp.2013.11.009_bib8","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1345\/aph.1R146","article-title":"Combination therapy for the treatment and prevention of hepatic encephalopathy","volume":"46","author":"Mohammad","year":"2012","journal-title":"Ann Pharmacother"},{"issue":"2","key":"10.1016\/j.mayocp.2013.11.009_bib9","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/ajg.2011.314","article-title":"Hospital readmissions among patients with decompensated cirrhosis","volume":"107","author":"Volk","year":"2012","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"10.1016\/j.mayocp.2013.11.009_bib10","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1111\/j.1572-0241.2001.03964.x","article-title":"Hepatic encephalopathy","volume":"96","author":"Blei","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.mayocp.2013.11.009_bib11","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1136\/bmj.38048.506134.EE","article-title":"Non-absorbably disaccharides for hepatic encephalopathy: systematic review of randomised trial","volume":"328","author":"Bodil","year":"2004","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.mayocp.2013.11.009_bib12","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/BF01072921","article-title":"Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy: a controlled, double-blind clinical trial","volume":"23","author":"Atterbury","year":"1978","journal-title":"Am J Digest Dis"},{"issue":"6","key":"10.1016\/j.mayocp.2013.11.009_bib13","first-page":"542","article-title":"Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy","volume":"39","author":"Strauss","year":"1992","journal-title":"Hepatogastroenterology"},{"issue":"2","key":"10.1016\/j.mayocp.2013.11.009_bib14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3350\/kjhep.2011.17.2.157","article-title":"Metronidazole-induced encephalopathy in a patient with liver cirrhosis","volume":"17","author":"Cheong","year":"2011","journal-title":"Korean J Hepatol"},{"issue":"3","key":"10.1016\/j.mayocp.2013.11.009_bib15","first-page":"195","article-title":"Two cases of metronidazole-induced encephalopathy [in Korean]","volume":"45","author":"Kim","year":"2005","journal-title":"Korean J Gastroenterol"},{"issue":"6","key":"10.1016\/j.mayocp.2013.11.009_bib16","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/gut.31.6.702","article-title":"Successful use of vancomycin hydrochloride in the treatment of lactulose resistant chronic hepatic encephalopathy","volume":"31","author":"Tarao","year":"1990","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.mayocp.2013.11.009_bib17","doi-asserted-by":"crossref","first-page":"455","DOI":"10.7326\/0003-4819-124-4-199602150-00015","article-title":"Metronidazole in treating portosystemic encephalopathy","volume":"124","author":"Uhl","year":"1996","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.mayocp.2013.11.009_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/gut.23.1.1","article-title":"Treatment of hepatic encephalopathy with metronidazole","volume":"23","author":"Morgan","year":"1982","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.mayocp.2013.11.009_bib19","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10096-008-0578-3","article-title":"Enterococcus: not an innocent bystander in cirrhotic patients with spontaneous bacterial peritonitis","volume":"28","author":"Lee","year":"2009","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"2","key":"10.1016\/j.mayocp.2013.11.009_bib20","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1185\/03007999309111539","article-title":"Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy","volume":"13","author":"Bucci","year":"1993","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"10.1016\/j.mayocp.2013.11.009_bib21","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00042737-200012020-00012","article-title":"Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study","volume":"12","author":"Williams","year":"2000","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.mayocp.2013.11.009_bib22","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3349\/ymj.2005.46.3.399","article-title":"Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study","volume":"46","author":"Paik","year":"2005","journal-title":"Yonsei Med J"},{"issue":"9","key":"10.1016\/j.mayocp.2013.11.009_bib23","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1038\/ajg.2013.219","article-title":"A\u00a0randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy","volume":"108","author":"Sharma","year":"2013","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"10.1016\/j.mayocp.2013.11.009_bib24","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1111\/j.1365-2036.2010.04448.x","article-title":"Clinical trial: oral zinc in hepatic encephalopathy","volume":"32","author":"Takuma","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.mayocp.2013.11.009_bib25","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1002\/hep.510230523","article-title":"Zinc supplementation and amino acid-nitrogen metabolism in patients with advanced cirrhosis","volume":"23","author":"Marchesini","year":"1996","journal-title":"Hepatology"},{"key":"10.1016\/j.mayocp.2013.11.009_bib26","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/S0011-393X(05)80681-2","article-title":"Rifaximin in the treatment of chronic hepatic en results of a multicenter study of efficacy and safety","volume":"54","author":"Festi","year":"1993","journal-title":"Current Therapeutic Research"},{"key":"10.1016\/j.mayocp.2013.11.009_bib27","first-page":"7","article-title":"Treatment of hepatic enwith rifaximin: Double-blind, double-dummy study versus lactulose","volume":"4","author":"Massa","year":"1993","journal-title":"Eur J Clin Res"},{"key":"10.1016\/j.mayocp.2013.11.009_bib28","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0168-8278(02)00350-1","article-title":"Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a ran double-blind, double-dummy, controlled clinical trial","volume":"38","author":"Mas","year":"2003","journal-title":"J Hepatol"},{"issue":"9","key":"10.1016\/j.mayocp.2013.11.009_bib29","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1007\/BF01307509","article-title":"Short-term oral zinc supplementation does not improve chronic hepatic encephalopathy: results of a double-blind crossover trial","volume":"36","author":"Riggio","year":"1991","journal-title":"Dig Dis Sci"},{"issue":"7","key":"10.1016\/j.mayocp.2013.11.009_bib30","first-page":"414","article-title":"Management of hepatic encephalopathy with oral zinc supplementation: a long-term treatment","volume":"2","author":"Bresci","year":"1993","journal-title":"Eur J Med"},{"issue":"8401","key":"10.1016\/j.mayocp.2013.11.009_bib31","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0140-6736(84)92567-4","article-title":"Oral zinc supplementation improves hepatic encephalopathy: results of a randomised controlled trial","volume":"2","author":"Reding","year":"1984","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.mayocp.2013.11.009_bib32","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/hep.510250609","article-title":"Therapeutic efficacy of l-ornithine-l-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study","volume":"25","author":"Kircheis","year":"1997","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.mayocp.2013.11.009_bib33","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/S0168-8278(98)80237-7","article-title":"Oral l-ornithine-l-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study","volume":"28","author":"Stauch","year":"1998","journal-title":"J\u00a0Hepatol"},{"issue":"11","key":"10.1016\/j.mayocp.2013.11.009_bib34","first-page":"666","article-title":"Efficacy of l-ornithine-l-aspartate as an adjuvant therapy in cirrhotic patients with hepatic encephalopathy","volume":"21","author":"Abid","year":"2011","journal-title":"J\u00a0Coll Physicians Surg Pak"},{"issue":"3","key":"10.1016\/j.mayocp.2013.11.009_bib35","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/hep.24412","article-title":"Branched-chain amino acids as pharmacological nutrients in chronic liver disease","volume":"54","author":"Kawaguchi","year":"2011","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.mayocp.2013.11.009_bib36","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S1542-3565(05)00017-0","article-title":"Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis","volume":"3","author":"Muto","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.mayocp.2013.11.009_bib37","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1016\/S0016-5085(03)00323-8","article-title":"Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial","volume":"124","author":"Marchesini","year":"2003","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.mayocp.2013.11.009_bib38","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S0168-8278(05)80210-7","article-title":"Long-term treatment of latent portosystemic encephalopathy with branched-chain amino acids: a double-blind placebo-controlled crossover study","volume":"17","author":"Plauth","year":"1993","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.mayocp.2013.11.009_bib39","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1038\/ajg.2011.9","article-title":"Effects of branched-chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study","volume":"106","author":"Les","year":"2011","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.mayocp.2013.11.009_bib40","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jhep.2004.03.023","article-title":"Normal protein diet for episodic hepatic encephalopathy: results of a randomized study","volume":"41","author":"Cordoba","year":"2004","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.mayocp.2013.11.009_bib41","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.clnu.2009.04.019","article-title":"ESPEN Guidelines on Parenteral Nutrition: hepatology","volume":"28","author":"Plauth","year":"2009","journal-title":"Clin Nutr"},{"issue":"6","key":"10.1016\/j.mayocp.2013.11.009_bib42","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1002\/hep.26314","article-title":"Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multicenter survey on safety and efficacy","volume":"57","author":"Laleman","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.mayocp.2013.11.009_bib43","doi-asserted-by":"crossref","unstructured":"Singh S, Kamath PS, Andrews JC, Leise MD. Embolization of spontaneous portosystemic shunts for management of severe persistent hepatic encephalopathy [published online June 14, 2013]. Hepatology. http:\/\/dx.doi.org\/10.1002\/hep.26575.","DOI":"10.1002\/hep.26575"},{"issue":"3","key":"10.1016\/j.mayocp.2013.11.009_bib44","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1002\/hep.26185","article-title":"Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial","volume":"57","author":"Banares","year":"2013","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.mayocp.2013.11.009_bib45","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1002\/hep.21930","article-title":"Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis","volume":"46","author":"Hassanein","year":"2007","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.mayocp.2013.11.009_bib46","doi-asserted-by":"crossref","first-page":"R8","DOI":"10.1186\/cc7697","article-title":"Albumin dialysis improves hepatic encephalopathy and decreases circulating phenolic aromatic amino acids in patients with alcoholic hepatitis and severe liver failure","volume":"13","author":"Pares","year":"2009","journal-title":"Crit Care"},{"issue":"2","key":"10.1016\/j.mayocp.2013.11.009_bib47","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/tid.12031","article-title":"Molecular Adsorbent Recirculating System (MARS\u00ae) removal of piperacillin\/tazobactam in a patient with acetaminophen-induced acute liver failure","volume":"15","author":"Ruggero","year":"2013","journal-title":"Transpl Infect Dis"},{"issue":"3","key":"10.1016\/j.mayocp.2013.11.009_bib48","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1053\/j.gastro.2009.05.056","article-title":"Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo","volume":"137","author":"Sharma","year":"2009","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.mayocp.2013.11.009_bib49","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/ajg.2012.113","article-title":"Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy","volume":"107","author":"Agrawal","year":"2012","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"10.1016\/j.mayocp.2013.11.009_bib50","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa0907893","article-title":"Rifaximin treatment in hepatic encephalopathy","volume":"362","author":"Bass","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.mayocp.2013.11.009_bib51","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1002\/hep.20905","article-title":"High prevalence of spontaneous portal-systemic shunts in persistent hepatic encephalopathy: a case-control study","volume":"42","author":"Riggio","year":"2005","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.mayocp.2013.11.009_bib52","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1053\/j.gastro.2010.02.015","article-title":"Persistence of cognitive impairment after resolution of overt hepatic encephalopathy","volume":"138","author":"Bajaj","year":"2010","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.mayocp.2013.11.009_bib53","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.cgh.2010.10.002","article-title":"Evidence of persistent cognitive impairment after resolution of overt hepatic encephalopathy","volume":"9","author":"Riggio","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.mayocp.2013.11.009_bib54","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/hep.23128","article-title":"Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test","volume":"50","author":"Bajaj","year":"2009","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.mayocp.2013.11.009_bib55","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2009.08.003","article-title":"Hepatic encephalopathy and fitness to drive","volume":"137","author":"Kircheis","year":"2009","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.mayocp.2013.11.009_bib56","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/hep.20095","article-title":"Minimal hepatic encephalopathy impairs fitness to drive","volume":"39","author":"Wein","year":"2004","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.mayocp.2013.11.009_bib57","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.cgh.2010.08.002","article-title":"Legal ramifications for physicians of patients who drive with hepatic encephalopathy","volume":"9","author":"Cohen","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.mayocp.2013.11.009_bib58","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/ajg.2011.154","article-title":"Minimal hepatic encephalopathy and driving: is the genie out of the bottle?","volume":"106","author":"Prakash","year":"2011","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.mayocp.2013.11.009_bib59","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1002\/hep.25507","article-title":"Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: a cost-effectiveness analysis","volume":"55","author":"Bajaj","year":"2012","journal-title":"Hepatology"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619613010380?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619613010380?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,7]],"date-time":"2018-10-07T11:22:06Z","timestamp":1538911326000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619613010380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S0025619613010380"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2013.11.009","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]}}}